Rockwell Medical reported 20% year-over-year net sales growth in Q3 2026, reflecting strong customer adoption of its hemodialysis concentrates. It posted a quarterly loss of $0.59 per share, wider than the $0.18 loss analysts expected and the $0.50 loss in the year-ago quarter. Despite the loss, revenue topped analysts’ estimates. The company expects combined annual revenue of $400 million to $450 million following the Vantive acquisition, which it is targeting to close by mid-2027.
The company targets mid-2027 for the acquisition closing, projecting a transformative shift in its annual revenue profile to between $400M and $450M.
Read the full storyGross profit rose 37% as volumes increased, but loss per share widened to $0.59 as the company awaits the Vantive deal, expected to close in mid-2027.
The company posted a smaller-than-expected adjusted per-share loss, but declining cash and the withdrawal of annual guidance put financing and execution of the Vantive deal under scrutiny.